Observational Study of Germ-Line Mutations in Cancer Patients
This research study is looking at genetic changes, called germ-line mutations, in blood and saliva samples from people with cancer. Doctors want to understand how these inherited genetic changes might increase the risk of developing cancer, affect how well treatments work, and play a role in cancer development. You may be able to join if you have a confirmed cancer diagnosis and are at least 18 years old. The main goals are to find out how common these genetic changes are and their overall frequencies, and to see how they relate to your response to treatment. The study aims to enroll 2000 participants.
- Study design
- This is an observational study, meaning participants are not given a specific treatment. It plans to enroll 2000 participants.
- What's involved
- You would provide blood and saliva samples 1-3 times. After the study, you will be followed for up to 5 years.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants are followed up for 5 years after completing the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Joanne Weidhaas · PRINCIPAL_INVESTIGATOR · Jonsson Comprehensive Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Prevalence of germ-line variantsUp to 5 years
The prevalence of germ-line variants of interest will be compared to the baseline prevalence found using available large human genomic DNA collections. The primary statistical analysis will involve comparisons of genotypes between with (cases) and without (controls) the germ-line mutation. This analysis will include Pearson's chi-square analysis or Fisher's exact test and computation of odds ratios to assess the relationship of the genetic polymorphism and cancer risk.
- Overall genotype frequenciesUp to 5 years
The overall genotype frequencies among the cases and expected control levels will first be compared with the frequencies expected from Hardy-Weinberg equilibrium by goodness-of-fit chi-square. Odds ratios and 95% confidence intervals will be used to estimate risk associated with the variant genotypes by using both univariate and unconditional multivariate logistic regression models.
- Response to treatmentUp to 5 years
The impact of inherited variants on response to treatment will be determined.
- Cancer developmentUp to 5 years
The role of inherited variants in clinical and pathological cancer development will be determined.